Deficient DMFs Jeopardizing Timely Approvals of ANDAs
Executive Summary
The pressure is on for API makers to submit higher quality Type II drug master files, or DMFs. FDA official says many US ANDA approvals are delayed by poor quality DMFs. A representative of the generic drug industry, however, contends that FDA is partially to blame for this problem by setting impractical expectations and an unrealistically high bar for DMFs.
You may also be interested in...
Updated US DMF Guidance Reflects GDUFA II, Electronic Submissions
US FDA’s first revision of its foundational Drug Master Files guidance in 30 years contains few surprises but incorporates statutory and regulatory actions. Among the changes: a new section requiring electronic submission of DMFs and a section reflecting GDUFA II completeness assessments in Type II DMFs.
Generic Sponsors Need To Increase Communications About Drug Master Files, US FDA Says
Industry complaining about issues in DMF completeness assessments, but few sponsors schedule teleconferences after complete response letters, FDA says.
Generic Sponsors Need To Increase Communications About Drug Master Files, US FDA Says
Industry complaining about issues in DMF completeness assessments, but few sponsors schedule teleconferences after complete response letters, FDA says.